Percutaneous Treatment of Tricuspid Regurgitation with the Novel TriFlO® Device: Technology and Clinical Update
Presenter:
We Recommend
Disclosures
Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:
- Consultant Fee/Honoraria/Speaker's Bureau - Abbott
- Equity/Stock(s)/Options - TRIFLO Cardiovascular